Studio sul Cabozantinib in Partecipanti con Tumori Neuroendocrini che Hanno Già Ricevuto un Trattamento Precedente (CaboLife)
CaboLife: Uno studio prospettico non interventistico sull'efficacia e sicurezza di Cabozantinib in contesto di vita reale per pazienti con tumore neuroendocrino precedentemente trattati
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Ipsen Clinical Study Enquiries
- Numero di telefono: See e mail
- Email: clinical.trials@ipsen.com
Luoghi di studio
-
-
-
Graz, Austria
- Reclutamento
- Medizinische Universitaet Graz
-
Linz, Austria
- Non ancora reclutamento
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, Austria
- Reclutamento
- Medizinische Universität Wien
-
-
-
-
-
Aschaffenburg, Germania
- Reclutamento
- MVZ am Klinikum Aschaffenburg
-
Berlin, Germania
- Reclutamento
- Evangelische Lungenklinik Berlin
-
Berlin, Germania
- Reclutamento
- DRK Kliniken Berlin
-
Berlin, Germania
- Reclutamento
- Charité - Universitaetsmedizin Berlin
-
Bonn, Germania
- Non ancora reclutamento
- Johanniter-Kliniken Bonn
-
Bremen, Germania
- Reclutamento
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Germania
- Non ancora reclutamento
- Klinikum Chemnitz
-
Cologne, Germania
- Reclutamento
- pioh Studien und Mangement GbR
-
Cologne, Germania
- Reclutamento
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Germania
- Reclutamento
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Germania
- Reclutamento
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Germania
- Reclutamento
- Universitaetsklinikum Erlangen
-
Essen, Germania
- Reclutamento
- Universitaetsklinikum Essen
-
Frankfurt, Germania
- Non ancora reclutamento
- Krankenhaus Nordwest
-
Frankfurt am Main, Germania
- Non ancora reclutamento
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Germania
- Reclutamento
- Universitaetsklinikum Freiburg
-
Giesen, Germania
- Non ancora reclutamento
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Germania
- Reclutamento
- Universitaetsmedizin Goettingen
-
Hamburg, Germania
- Reclutamento
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Germania
- Non ancora reclutamento
- Asklepios Kliniken Hamburg
-
Heidelberg, Germania
- Non ancora reclutamento
- Universitaetsklinikum Heidelberg
-
Kiel, Germania
- Non ancora reclutamento
- UKSH Kiel
-
Leer, Germania
- Non ancora reclutamento
- Studienzentrum UnterEms
-
Leipzig, Germania
- Non ancora reclutamento
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Germania
- Non ancora reclutamento
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Germania
- Reclutamento
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Germania
- Non ancora reclutamento
- UKSH Luebeck
-
Mainz, Germania
- Non ancora reclutamento
- Universitaetsmedizin Mainz
-
Marburg, Germania
- Reclutamento
- Philipps-Universitaet Marburg
-
Minden, Germania
- Reclutamento
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Germania
- Reclutamento
- MVZ Muelheim an der Ruhr GmbH
-
München, Germania
- Non ancora reclutamento
- TUM Klinikum Muenchen
-
Münster, Germania
- Non ancora reclutamento
- Universitaetsklinikum Muenster
-
Osnabrück, Germania
- Non ancora reclutamento
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Germania
- Non ancora reclutamento
- Universitaestklinikum Saarbruecken
-
Tübingen, Germania
- Reclutamento
- Universitätsklinikum Tuebingen
-
Westerstede, Germania
- Reclutamento
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Germania
- Reclutamento
- Universitaetsklinikum Wuerzburg
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
Descrizione
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease Control Rate (DCR)
Lasso di tempo: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Lasso di tempo: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Lasso di tempo: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Lasso di tempo: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Lasso di tempo: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Lasso di tempo: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Lasso di tempo: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Lasso di tempo: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Lasso di tempo: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Lasso di tempo: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Lasso di tempo: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Lasso di tempo: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Ipsen Medical Director, Ipsen
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CLIN-60000-467
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Periodo di condivisione IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
Criteri di accesso alla condivisione IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .